Ethicon Physiomesh Claims Selected as Trial Pool Cases in Federal MDL

|

A group of ten Ethicon Physiomesh lawsuits have been selected for a bellwether trial pool in the federal court system, where there cases will be prepared for a series of early trial dates to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout thousands of claims brought by individuals who experienced problems with the recalled hernia mesh.

Johnson & Johnson and its Ethicon subsidiary face nearly 2,000 product liability lawsuits over hernia mesh complications associated with the flexible composite mesh, which was removed from the market in May 2016, following an alarming number of reports involving abdominal pain, infection, hernia recurrence, adhesions, perforations, erosion and failure of the mesh. In most of the cases, plaintiffs required additional surgery to remove the mesh or repair damage that it caused.

Given similar questions of fact and law raised in complaints filed throughout the federal court system, the Ethicon Physiomesh cases are centralized for pretrial proceedings before U.S. District Judge Richard Story in the Northern District of Georgia, as part of an MDL, or multidistrict litigation. The process is designed to reduce duplicative discovery into common issues in the cases, avoid conflicting rulings from different courts and to serve the convenience of parties, witnesses and the judicial system.

Is there a hernia mesh lawsuit? Find out if you qualify for a hernia mesh lawsuit settlement payout.
Is there a hernia mesh lawsuit? Find out if you qualify for a hernia mesh lawsuit settlement payout.

As part of the coordinated management of the litigation, Judge Story has previously established a bellwether program, which will result in a series of trials early next year, which will be used by the parties to gauge the relative strengths and weaknesses of their case.

In a notice (PDF) posted on May 10, a group of ten cases were identified, which are part of a bellwether trial pool, from which the first claims will be selected to go before a jury starting in February 2020. The pool includes five cases selected by each side, which are designed to be representative of issues that will be presented throughout the litigation.

While the outcomes for these test trials will not be binding on other claims, they are designed to help the parties gauge the relative strengths and weaknesses of cases, facilitating potential hernia mesh settlements that may avoid the need for hundreds of individual trials nationwide.

As lawyers continue to review additional claims for individuals who have experienced problems following a hernia repair, the number of Ethicon Physiomesh cases filed in the federal court system is expected to continue to increase. Following the bellwether trials, if the manufacturer fails to settle the cases or otherwise resolve the litigation, each individual case may be remanded back to the U.S. District Court where it was originally filed for a separate trial date in the future.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

A West Virginia woman’s lawsuit over complications with a Cartiva implant has been scheduled to go before a jury in February 2026, involving claims that the big toe implant failed just weeks before the manufacturer issued a Cartiva recall.
A federal judge has rejected a motion to dismiss claims involving wrongful death and negligence raised in lawsuits over social media addiction brought by families throughout the U.S.
A group of eight lawyers have been recommended to serve in various leadership positions in the Biozorb litigation, taking actions that benefit all plaintiffs pursuing cases over injuries caused by the recalled breast tissue marker.